Monoclonal Antibodies Targeting NKG2A in Cancer Immunotherapy

Cancer immunotherapy has revolutionized oncology by harnessing the immune system to recognize and destroy malignant cells. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have produced durable responses in many cancers, yet a large fraction of patients remain resistant. A major reason for this resistance is that tumors suppress not only T-cell immunity but also innate immune surveil...